# InfuSystem Holdings, Inc. (INFU)

> Source: Nexqual · https://nexqual.com/INFU · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, InfuSystem Holdings, Inc. (INFU), nexqual.com/INFU" · informational, not investment advice.

**Price:** USD 14.14 (+0.64% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 14.05 · day 13.9–14.41 · 52w 7.29–14.41 · market cap $282M · ASE

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $143M, net income $8.5M (6.0% margin), free cash flow $22.9M (SEC filings).
- Valuation: P/E 33.0x (avg 122.8x at the last 3 fiscal year-ends), EV/EBITDA 11.4x, net debt $19.5M.
- 1 of 80 tracked superinvestors hold INFU (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 16.83 (range 15–18).
- Total return with dividends: 1Y +40.6% vs S&P 500 +14.9%; 5Y -1.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.12, revenue estimate $37.3M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $102M | $110M | $126M | $135M | $143M | $143M |
| Gross profit | $58.5M | $60.6M | $63.1M | $70.4M | $80.3M | — |
| Operating income | $2.8M | $1.7M | $4.1M | $6.9M | $11.9M | $13.3M |
| Net income | $1.4M | $18K | $872K | $2.3M | $6.6M | $8.5M |
| EPS (diluted) | $0.06 | $0.00 | $0.04 | $0.11 | $0.31 | — |
| Free cash flow | $17.3M | $16.5M | $10.2M | $19.4M | $23.8M | $22.9M |
| Gross margin | 57.2% | 55.1% | 50.2% | 52.2% | 56.0% | — |
| Operating margin | 2.8% | 1.5% | 3.2% | 5.1% | 8.3% | 9.3% |
| Net margin | 1.4% | 0.0% | 0.7% | 1.7% | 4.6% | 6.0% |
| Revenue growth | +5.1% | +7.4% | +14.4% | +7.2% | +6.4% | — |
| Cash + short-term investments | $186K | $165K | $231K | $527K | $3.2M | — |
| Total debt | $33.1M | $33.2M | $29.1M | $23.9M | $19.6M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 33.0x · P/S 2.0x · EV/EBITDA 11.4x · EV/Sales 2.1x · P/FCF 12.3x · P/B 4.8x · FCF yield 8.13% · Earnings yield 3.03% · Buyback yield (TTM) 2.78% · Net debt $19.5M · EV $301M
P/E at fiscal year-ends: Dec 2025 28.6x, Dec 2024 78.2x, Dec 2023 261.6x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold INFU. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $6.0M | Reduced -14.1% |

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 16.83 (low 15, high 18).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-05 | B. Riley Securities | Target raised | Buy | $12 → $20 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +40.6% | -1.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +40.7% | -0.3% |
| Volatility (annualized) | 54.9% | 54.6% |
| Max drawdown | -29.5% (Oct 2025→Feb 2026) | -72.9% (Nov 2021→Apr 2025) |

## Peers (Medical Devices)
NVCR (NovoCure Limited) USD 15.1 -3.14% · BFLY (Butterfly Network, Inc.) USD 6.81 -4.08% · ESTA (Establishment Labs Holdings Inc) USD 63.52 +1.99% · ALMR (Alamar Biosciences, Inc.) USD 29.72 -5.50% · INSP (Inspire Medical Systems, Inc.) USD 72.66 +2.24% · AXGN (AxoGen, Inc.) USD 36.68 +0.55%

## More
Full page: https://nexqual.com/INFU · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.12 | $0.00 | — | $37.3M | 1 |
| Next quarter (ends 2026-12-31) | $0.14 | $0.00 | — | $37.3M | 1 |
| Current fiscal year (ends 2026-12-31) | $0.46 | $0.00 | — | $145.2M | 1 |
| Next fiscal year (ends 2027-12-31) | $0.52 | $0.00 | — | $154.1M | 1 |